Quantcast

Industry news that matters to you.  Learn more

Genomic Health Presents Twenty Two International Studies Demonstrating Worldwide Adoption and Value of Oncotype DX® Breast Cancer Test

Genomic Health, Inc. (Nasdaq: GHDX) recently announced the presentation of results from 22 studies at the 13th St. Gallen International Breast Cancer Conference highlighting the impact of the Oncotype DX® breast cancer test around the world. New data continue to demonstrate the test’s ability to change treatment decisions and provide economic value across multiple health care systems, while reinforcing its clinical validation, accuracy and precision. This unparalleled number of studies and consistency of results emphasize the benefit that the Oncotype DX test provides in breast cancer as the only genomic test shown to predict chemotherapy benefit.

Vitamin D Holds Promise In Battling A Deadly Breast Cancer, Saint Louis University Researchers Say

In research published in the Jan. 21 issue of The Journal of Cell Biology, a team led by Susana Gonzalo, Ph.D., assistant professor of biochemistry and molecular biology at Saint Louis University, has discovered a molecular pathway that contributes to triple-negative breast cancer, an often deadly and treatment resistant form of cancer that tends to strike younger women. In addition, Gonzalo and her team identified vitamin D and some protease inhibitors as possible new therapies and discovered a set of three biomarkers that can help to identify patients who could benefit from the treatment.

UT MD Anderson Research Finds Predictive Value of Circulating Tumor Cells in Early Stage Breast Cancer

Circulating tumor cells (CTCs), established in the metastatic breast cancer setting for predicting a woman’s chance of recurrence and survival, have now shown similar value in early stage breast cancer, according to research from The University of Texas MD Anderson Cancer Center.

Genomic Health Announces Results from Fourteen Studies Emphasizing Belief of Physicians around the World in the Value of Oncotype DX

Genomic Health, Inc. today announced the presentation of results from fourteen studies at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) reinforcing the impact of the Oncotype DX breast cancer test on changing treatment decisions and demonstrating its cost effectiveness across multiple health care systems. Additionally, data continues to reconfirm the accuracy, precision, reproducibility and consistency of the Recurrence Score (RS) results in patients with early-stage breast cancer. Presentations included ten international studies from the United Kingdom, Germany, France, Ireland, Australia, Venezuela, and a review including data from Israel, Canada, Hungary, Japan, and Singapore.

Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients

Biocept, Inc., a privately-held CLIA-certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs) in cancer patients, and Clarient, Inc. (a GE Healthcare Company) today announced a collaboration on the commercialization of a proprietary blood test for CTCs in breast cancer patients, which includes the determination of HER2 status. Clarient and Biocept will market and sell Biocept’s new OncoCEE-BR CTC test to community hospitals, pathologists and medical oncologists. Biocept will perform the test in its laboratories, and results will be interpreted by Clarient’s highly respected pathology group (Clarient Pathology Services, Inc.). The test includes CTC enumeration and HER2 status of the detected CTCs by fluorescence in situ hybridization (FISH); it is the first commercially available CTC test to include analysis of a specific treatment-associated biomarker.